UAMY Stock Slides As Earnings Miss Fuels Volatility

United States Antimony Corporation stocks have been trading down by -10.76 percent amid heightened concerns over declining antimony demand.

Live Update At 14:02:11 EDT: On Friday, May 15, 2026 United States Antimony Corporation stock [NYSE: UAMY] is trending down by -10.76%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

United States Antimony Corporation just delivered the kind of quarter that forces traders to read the fine print. UAMY reported Q1 revenue of $6.8M, badly missing the $14.8M consensus. On the bottom line, the company logged a loss of $0.08 per share, versus breakeven a year ago and expectations for only a $0.02 loss. That is not a small miss — it is a major reset on near-term expectations.

Despite that, UAMY still carries a rich price-to-sales ratio around 36. For a company with negative earnings and cash flow, that tells traders the stock has been priced for big future growth, not current performance. Profitability metrics back up the pressure: EBIT margin stands at about -11%, and net margins are also deeply negative. Returns on equity and assets are both in the red.

More Breaking News

• UiPath (PATH) Stock Climbs As AI Partnerships Power Momentum
• VG Stock Jumps As New LNG Deals Boost Q1 Momentum
• Navitas Semiconductor Stock Rockets On AI Power, Analyst Upgrades
• SEDG Stock Pops As Earnings Recovery Meets CFO Shake-Up

On the balance sheet side, UAMY looks stronger. The company shows no long-term debt pressure, a current ratio above 5, and significant working capital. That gives United States Antimony room to ride out volatility, but it does not erase execution risk. For traders, this is a classic high-expectation, low-profit story where timing and risk control matter.

Why Traders Are Watching UAMY After The Miss

The latest earnings from UAMY explain why the stock has turned into a volatility magnet. United States Antimony came into 2026 with aggressive growth targets, including a reiterated 2026 gross revenue goal of $125M. But when Q1 revenue lands at just $6.8M — less than half of what analysts expected — traders start asking tough questions about the path from here to there.

The market’s first response was clear. UAMY traded about 3% lower in after-hours after the 2026/05/14 report. For a stock that had been running — note the recent swing from a high above $12 on 2026/05/01 to $8.54 at the close on 2026/05/15 — that drop fit right into an emerging downtrend. The daily chart shows UAMY rolling over from the low $12s to the mid $8s in two weeks, a sign that momentum players are already backing off.

Intraday action on 2026/05/15 confirms that cooling. UAMY opened near $9.34 and faded toward $8.54, with tight 5‑minute candles clustering around the mid‑$8s. That kind of choppy, grinding downside tells active traders that dip buyers are less aggressive, while short‑biased traders are probing weakness.

At the same time, UAMY’s strong balance sheet and reaffirmed 2026 revenue target keep the story alive. Long-term‑oriented traders see potential if United States Antimony can close the gap between its current $6.8M quarter and its $125M goal. Short-term players, though, will focus on whether the next few quarters show any real traction on sales and margins. Until then, UAMY is a “prove it” stock where news and guidance can trigger sharp moves in either direction.

Conclusion

For active traders, UAMY now sits at the crossroads of hype and hard numbers. United States Antimony’s Q1 performance — a $0.08 per-share loss and revenue less than half of consensus — undercuts the near-term bull case. The slide from the $12 area to the mid‑$8s, plus the 3% after-hours drop on 2026/05/14, shows the market is recalibrating expectations fast.

Yet the UAMY story is not dead. Management’s decision to reiterate the 2026 $125M gross revenue target tells traders the long-term thesis remains intact internally. The clean balance sheet, with no meaningful long-term debt and solid liquidity, gives United States Antimony time to execute. The question now is simple: does the company start closing the gap between promise and performance over the next few quarters?

For short-term trading, UAMY is now all about levels, catalysts, and discipline. Weak earnings, rich valuation, and heavy volatility can be a dangerous mix for anyone who overstays. As Tim Sykes and Tim Bohen often stress, “the market doesn’t care about your opinion; it cares about price action and catalysts.” That’s where having a personal trading mantra matters: As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” With UAMY, the catalysts are clear, the price action is noisy, and traders who respect risk will be the ones still standing when the next headline hits.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.